Department of Hepatology, Asian Institute of Gastroenterology, Hyderabad, India.
Department of Liver Transplantation and Hepatobiliary Surgery, Asian Institute of Gastroenterology, Hyderabad, India.
Am J Transplant. 2021 Jun;21(6):2279-2284. doi: 10.1111/ajt.16509. Epub 2021 Feb 15.
COVID-19 (coronavirus disease 2019) has impacted solid organ transplantation (SOT) in many ways. Transplant centers have initiated SOT despite the COVID-19 pandemic. Although it is suggested to wait for 4 weeks after COVID-19 infection, there are no data to support or refute the timing of liver transplant after COVID-19 infection. Here we describe the course and outcomes of COVID-19-infected candidates and healthy living liver donors who underwent transplantation. A total of 38 candidates and 33 potential living donors were evaluated from May 20, 2020 until October 30, 2020. Ten candidates and five donors were reverse transcriptase-polymerase chain reaction (RT-PCR) positive for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pretransplant. Four candidates succumbed preoperatively. Given the worsening of liver disease, four candidates underwent liver transplant after 2 weeks due to the worsening of liver disease and the other two candidates after 4 weeks. Only one recipient died due to sepsis posttransplant. Three donors underwent successful liver donation surgery after 4 weeks of COVID-19 infection without any postoperative complications, and the other two were delisted (as the candidates expired). This report is the first to demonstrate the feasibility of elective liver transplant early after COVID-19 infection.
COVID-19(冠状病毒病 2019)以多种方式影响实体器官移植(SOT)。移植中心已经在 COVID-19 大流行期间启动了 SOT。尽管建议在 COVID-19 感染后等待 4 周,但没有数据支持或反驳 COVID-19 感染后进行肝移植的时间。在这里,我们描述了 COVID-19 感染候选人和接受移植的健康活体肝供体的病程和结局。共有 38 名候选人和 33 名潜在的活体供体从 2020 年 5 月 20 日至 2020 年 10 月 30 日进行了评估。10 名候选人和 5 名供体在移植前逆转录-聚合酶链反应(RT-PCR)检测到严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)呈阳性。4 名候选者在术前死亡。由于肝病恶化,4 名候选者在 2 周后因肝病恶化而进行肝移植,另外 2 名候选者在 4 周后进行肝移植。只有 1 名受者在移植后因败血症死亡。3 名供体在 COVID-19 感染后 4 周成功进行了肝移植手术,没有任何术后并发症,另外 2 名供体被除名(因候选者死亡)。本报告首次证明了 COVID-19 感染后早期进行选择性肝移植的可行性。